Announcements Trials
Browse Landscape

Phase

Phase 4 1Phase 3 1Phase 2 1

Status

Completed 2Not yet recruiting 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Thoracic 3Gynecologic 1

Conditions

Ovarian Neoplasms 3Lung Neoplasms 3

Interventions

Carboplatin 98Pemetrexed 70pembrolizumab 68Cisplatin 59Paclitaxel 54Docetaxel 45Gemcitabine 37Erlotinib Hydrochloride 24Nivolumab 23osimertinib 17Bevacizumab 17durvalumab 14Cetuximab 13130-nm albumin-bound paclitaxel 13Gefitinib 11Etoposide 11Drug Therapy 11Ipilimumab 9Injections 9Albumin-Bound Paclitaxel 9Vinorelbine 8Radiotherapy 8motexafin gadolinium 7capmatinib 7atezolizumab 7epacadostat 6Taxes 6Cyclophosphamide 6vandetanib 5entinostat 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
INDUSTRY × Lung Neoplasms × Pafolacianine × Clear all
NCT07469202 2026-03-13

CYTALUX Dose Extension Study

On Target Laboratories, LLC

Phase 4 Not yet recruiting
106 enrolled
GynecologicThoracic

Lung Neoplasms, Ovarian Neoplasms

NCT02872701 2023-03-24

OTL38 Injection for Intraoperative Imaging of Folate Receptor Positive Lung Nodules

On Target Laboratories, LLC

Phase 2 Completed
100 enrolled 15 charts
Thoracic

Lung Neoplasms

NCT04241315 2023-03-23

Elucidate

On Target Laboratories, LLC

Phase 3 Completed
112 enrolled 15 charts
Thoracic

Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡